Company
Headquarters: Haikou, China
Employees: 848
CN¥4.02 Billion
CNY as of Jan. 1, 2025
US$550.9 Million
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Hainan Poly Pharm. Co., Ltd. researches and develops, produces, and sells pharmaceutical products in China. The company offers APIs. The company offers formulations in various therapeutic areas, which include anti-allergy, non-steroid anti-inflammatory, antibiotic, and digestive drugs. Its products include desloratadine preparations in anti-allergy drugs, diclofenac preparations in non-steroidal anti-inflammatory drugs, azithromycin for injection and clarithromycin preparations in antibiotic drugs, and trimebutine maleate preparations in digestive drugs. The company was founded in 1992 and is based in Haikou, China.
Hainan Poly Pharm. Co. Ltd has the following listings and related stock indices.
Stock: SZSE: 300630 wb_incandescent